New drug aims to shield autoimmune patients from Life-Threatening infections
NCT ID NCT07220915
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 28 times
Summary
This study tests whether Panzyga, an antibody treatment, can prevent major infections in 360 adults with autoimmune or rheumatic conditions who have low antibody levels and are receiving B-cell depletion therapy. Participants will receive either Panzyga or a placebo, and researchers will track how many develop serious infections. The goal is to reduce infection risk while managing the underlying disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.